Jazz Pharmaceuticals JAZZ EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's EPS (basic)?
- Jazz Pharmaceuticals (JAZZ) reported EPS (basic) of $4.73 in Q1 2026.
- How has Jazz Pharmaceuticals's EPS (basic) changed year-over-year?
- Jazz Pharmaceuticals's EPS (basic) increased by 411.2% year-over-year, from -$1.52 to $4.73.
- What is the long-term trend for Jazz Pharmaceuticals's EPS (basic)?
- Over 3 years (2021 to 2024), Jazz Pharmaceuticals's EPS (basic) has grown at a 19.3% compound annual growth rate (CAGR), from -$5.35 to $9.08.
- What does EPS (basic) mean?
- The amount of profit earned for each share of common stock outstanding.
- How do you interpret EPS (basic)?
- An increase indicates improved profitability per share, while a decrease suggests declining earnings or share dilution.
- How does EPS (basic) compare across companies?
- Standardized across all public companies; investors compare this against historical trends and analyst consensus estimates.